158 related articles for article (PubMed ID: 38594678)
1. Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study.
Li W; Ma L; Li F; Li K; Zhang Y; Ren H; Bao X; Guo Y; Guo Y; Wang M; Li D; Duan Y; Ma X; Wang Z; Wang Y; Yin R
Radiat Oncol; 2024 Apr; 19(1):46. PubMed ID: 38594678
[TBL] [Abstract][Full Text] [Related]
2. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.
Lewis S; Chopra S; Naga P; Pant S; Dandpani E; Bharadwaj N; Mahantshetty U; Engineer R; Swamidas J; Ghosh J; Gupta S; Shrivastava S
Br J Radiol; 2018 Dec; 91(1092):20180005. PubMed ID: 30179056
[TBL] [Abstract][Full Text] [Related]
3. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
Huang J; Gu F; Ji T; Zhao J; Li G
Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
[TBL] [Abstract][Full Text] [Related]
4. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
Klopp AH; Moughan J; Portelance L; Miller BE; Salehpour MR; Hildebrandt E; Nuanjing J; D'Souza D; Souhami L; Small W; Gaur R; Jhingran A
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):83-90. PubMed ID: 23582248
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
[TBL] [Abstract][Full Text] [Related]
6. A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.
Chen H; Zhong Q; Liu Y; Li J; Deng W; Wang J; Zhou S; Yu Z; Huang X; Huang Y; Zhen B; Wei J; Zhang W; Ruan X; Xiao L
Radiat Oncol; 2023 Nov; 18(1):193. PubMed ID: 38012675
[TBL] [Abstract][Full Text] [Related]
7. Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review.
Corbeau A; Kuipers SC; de Boer SM; Horeweg N; Hoogeman MS; Godart J; Nout RA
Radiother Oncol; 2021 Nov; 164():128-137. PubMed ID: 34560187
[TBL] [Abstract][Full Text] [Related]
8. Single-photon emission computed tomography-defined active bone marrow-sparing volumetric-modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single-center prospective randomized controlled trial.
Wang S; Liu J; Lei K; Jia Y; Wang C; Zhang X; Li T
Cancer; 2023 Jul; 129(13):1995-2003. PubMed ID: 37043337
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
[TBL] [Abstract][Full Text] [Related]
10. Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial.
Williamson CW; Sirák I; Xu R; Portelance L; Wei L; Tarnawski R; Mahantshetty U; Heide ES; Yashar CM; McHale MT; Bosch W; Lowenstein J; Saenz CC; Plaxe S; Eskander R; Einck J; Mundt AJ; Mayadev J; Mell LK
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):169-178. PubMed ID: 34419564
[TBL] [Abstract][Full Text] [Related]
11. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
Wan J; Liu K; Li K; Li G; Zhang Z
Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
[TBL] [Abstract][Full Text] [Related]
12. The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy.
Chen M; Wang D; Bao Z; Yi Z; Mei Z; Sun S; Xiang Q; Yang C; Yang H; Qiu H; Xie C
Radiat Oncol; 2023 Apr; 18(1):66. PubMed ID: 37031167
[TBL] [Abstract][Full Text] [Related]
13. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
[TBL] [Abstract][Full Text] [Related]
14. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation.
Sini C; Fiorino C; Perna L; Noris Chiorda B; Deantoni CL; Bianchi M; Sacco V; Briganti A; Montorsi F; Calandrino R; Di Muzio N; Cozzarini C
Radiother Oncol; 2016 Jan; 118(1):79-84. PubMed ID: 26702990
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of VMAT and IMRT Techniques: Evaluation of Dose Constraints and Bone Marrow Sparing in Cervical Cancer Patients Undergoing Chemoradiotherapy.
Thakur N; Kaur H; Kaur S; Lehal P; Sudan M; Jain N; Sharma R; Sharma A
Asian Pac J Cancer Prev; 2024 Jan; 25(1):139-144. PubMed ID: 38285777
[TBL] [Abstract][Full Text] [Related]
16. Development of a nomogram for predicting grade 2 or higher acute hematologic toxicity of cervical cancer after the pelvic bone marrow sparing radiotherapy.
Meng X; Wang N; Yu M; Kong D; Zhang Z; Chang X; Guo Y; Li Y
Front Public Health; 2022; 10():993443. PubMed ID: 36159246
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.
Mell LK; Tiryaki H; Ahn KH; Mundt AJ; Roeske JC; Aydogan B
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1504-10. PubMed ID: 18640499
[TBL] [Abstract][Full Text] [Related]
18. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
[TBL] [Abstract][Full Text] [Related]
19. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
[TBL] [Abstract][Full Text] [Related]
20. The volume of
Wang SB; Liu JP; Lei KJ; Jia YM; Xu Y; Rong JF; Wang CX
Cancer Med; 2019 Dec; 8(17):7219-7226. PubMed ID: 31621208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]